Sander Slootweg, Forbion managing partner and co-founder

Eu­ro­pean biotech VC For­bion clos­es two funds at $1.5B to­tal in its biggest rais­es to date

Eu­ro­pean life sci­ences ven­ture cap­i­tal firm For­bion has closed two of its funds — one ear­ly-stage and one late-stage — at €750 mil­lion (about $823 mil­lion USD) and €600 mil­lion ($658 mil­lion USD) re­spec­tive­ly, it an­nounced Wednes­day morn­ing.

For­bion ini­tial­ly closed its late-stage fund in June at €470 mil­lion be­fore reach­ing the hard cap on the fund at €600 mil­lion. Known as the For­bion Growth Op­por­tu­ni­ties Fund, the raise was For­bion’s sec­ond late-stage spe­cif­ic fund. With the mon­ey, For­bion plans to in­vest up to €70 mil­lion per deal, and For­bion man­ag­ing part­ner and co-founder Sander Slootweg said the firm plans to in­vest in 12 to 15 com­pa­nies via that fund.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.